A clinical whole-genome sequencing test for patients with multiple myeloma, JAYseq, has been launched at the Translational Genomics Research Institute (TGen).
“The launch of JAYseq represents a meaningful step in oncology testing, one that allows physicians to make a more precise treatment decision for patients facing one of the most complex blood cancers,” said Jeffrey M. Trent, PhD, President and Research Director of TGen. “By delivering a full genomic profile in under 72 hours, we are accelerating the diagnostic steps that have historically prevented timely intervention.”
JAYseq, powered by the proprietary ALTseq technology at TGen, is a comprehensive whole-genome sequencing test for detecting genomic features among patients with newly diagnosed or relapsed/refractory multiple myeloma and related plasma cell dyscrasia. The one test can replace several fluorescence in situ hybridization and cytogenetic tests currently used for multiple myeloma care, and has a turnaround time of 72 hours.
The test identifies the presence or absence of significant immunotherapy target antigens and determines high-risk status by International Myeloma Society (IMS)–International Myeloma Working Group (IMWG) consensus, enabling genomically informed treatment selection for each patient.
“For the first time, JAYseq allows us to view the full genomic blueprint of each multiple myeloma tumor. This enables us to identify not only why a specific therapy might succeed, but also which mutations could cause it to fail,” said Jonathan Keats, PhD, Associate Professor in the Clinical Genomics and Therapeutics Division at TGen and Scientific Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope. “This level of detail is essential for truly individualizing cancer care.”
JAYseq uses high-throughput next-generation sequencing to perform whole-genome sequencing and simultaneously detect genetic changes from single nucelotide variants to large-scale copy number alterations, structural variants, and hyperdiploid status.
The fast, comprehensive testing can guide the use of risk-adapted treatment approaches, including mutation-specific therapies and immunotherapy, enabling more personalized treatment decisions.
Additionally, results from JAYseq are provided in an easy-to-interpret clinical report to make complex genomic information clearer for clinicians.
“In the era of targeted therapies with multiple approved CAR-T and bispecific therapies it is essential that our decisions incorporate the unique features of each patients tumor,” said Amrita Krishnan, MD, the Nason-Hollingsworth Chair in Multiple Myeloma and Executive Medical Director, Hematology, City of Hope Orange County and Director of the Judy and Bernard Briskin Multiple Myeloma Center. “JAYseq provides the clarity and speed we’ve been missing, allowing us to tailor therapy with a level of precision that simply wasn’t possible before.”
JAYseq is available now through the TGen Clinical Laboratory.
